AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 22 min read$UTHR

ROTHBLATT MARTINE A sold $5.3M of UTHR

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $554.61 ($548.01–$558.37, $5.27M total) across 11 trades on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Jul 2, 2026, 9:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The newest fact is the CEO/Chair’s same-day sale details (shares, price range, total value) and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for sentiment effects, but the 10b5-1 framing generally limits fundamental interpretation.

03

What to watch

The filing does not disclose reasons for the sale or any offsetting insider buys; without additional context, interpret cautiously.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (2026-07-02)

Background

The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

SEC Form 4 shows UTHR CEO/Chair Martine Rothblatt sold 9,500 shares on 2026-07-02 under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction with a stated 10b5-1 pre-arranged plan, reducing interpretive weight versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    United Therapeutics Corp

    Subject of the Form 4 insider transaction; CEO/Chair Martine Rothblatt sold shares on 2026-07-02.

  • insider
    Martine A. Rothblatt

    Chairperson & CEO who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 5
$UTHRMed

UNITED THERAPEUTICS ($UTHR) Releases Q2 2026 Earnings

United Therapeutics (UTHR) reported Q2 2026 earnings of $7.27 per share, above the $6.97 estimate. Revenue was $783.3 million, below the $821.8 million estimate. The article also cites insider sales totaling 1,373 trades over six months, and notes a median analyst price target of $660.

quiverquant.com4 min
AUG 5
$UTHRMed

UNITED THERAPEUTICS Corp (UTHR): Results of Operations and Financial Condition

UNITED THERAPEUTICS Corp (UTHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 uthrq22026-ex991.htm EX-99.1 Document Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Second Quarter 2026 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., August 5, 2026: United Therapeutics Corporation (Nasdaq: UTHR ), a

SEC EDGAR 8-K7 min